Voyager Therapeutics

VYGRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$197.578 M

$3.27 +4.47%

Close of 7 Aug 2026

Revenue

$40.4M

#2809 by revenue

Earnings

-$119.7M

Loss-making

Shares outstanding

61,617,948

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#95Protalix BioTherapeuticsPLX$198.2M
#96AlectorALEC$197.6M
#97Voyager TherapeuticsVYGR$197.6M
#98Coherus OncologyCHRS$196.2M
#99Precision BiosciencesDTIL$193.3M

Where these numbers come from

Share counts and financials for Voyager Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.